And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
big pharma companies attending conference, they are presented with strong positive results, they digest the results and come up with a buy out offer. AMBS could well see $$$$ at that point. IMO